关注
Marek Brzosko
Marek Brzosko
profesor medycyny
在 pum.edu.pl 的电子邮件经过验证
标题
引用次数
引用次数
年份
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double‐blind treatment phase of a …
JM Kremer, R Blanco, M Brzosko, R Burgos‐Vargas, AM Halland, ...
Arthritis & Rheumatism 63 (3), 609-621, 2011
5412011
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
W Park, DH Yoo, P Miranda, M Brzosko, P Wiland, S Gutierrez-Ureña, ...
Annals of the rheumatic diseases 76 (2), 346-354, 2017
2982017
Three multicenter, randomized, double‐blind, placebo‐controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis
A Deodhar, LS Gensler, J Sieper, M Clark, C Calderon, Y Wang, Y Zhou, ...
Arthritis & Rheumatology 71 (2), 258-270, 2019
2972019
Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double‐blind, placebo‐controlled trials
MEB Clowse, DJ Wallace, RA Furie, MA Petri, MC Pike, P Leszczyński, ...
Arthritis & rheumatology 69 (2), 362-375, 2017
2282017
The expansion of CD4+CD28- T cells in patients with rheumatoid arthritis
A Pawlik, L Ostanek, I Brzosko, M Brzosko, M Masiuk, B Machalinski, ...
Arthritis Res Ther 5, 1-4, 2003
1522003
Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year …
RM Fleischmann, AM Halland, M Brzosko, R Burgos-Vargas, C Mela, ...
The Journal of rheumatology 40 (2), 113-126, 2013
1232013
Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib
R Lehmann, M Brzosko, P Kopsa, R Nischik, A Kreiss, H Thurston, ...
Current medical research and opinion 21 (4), 517-526, 2005
892005
Serum IL‐6 and IL‐23 levels and their correlation with angiogenic cytokines and disease activity in ankylosing spondylitis, psoriatic arthritis, and SAPHO syndrome
H Przepiera-Będzak, K Fischer, M Brzosko
Mediators of inflammation 2015 (1), 785705, 2015
822015
Cardiac arrhythmias and conduction disturbances in patients with ankylosing spondylitis
J Kaźmierczak, M Peregud-Pogorzelska, J Biernawska, ...
Angiology 58 (6), 751-756, 2007
592007
TNF-α-308 promoter polymorphism in patients with rheumatoid arthritis.
A Pawlik, M Florczak, L Ostanek, M Brzosko, I Brzosko, BG Szklarz
Scandinavian journal of rheumatology 34 (1), 2005
562005
Is prevalence of PBC underestimated in patients with systemic sclerosis?
GL Norman, A Bialek, S Encabo, B Butkiewicz, A Wiechowska-Kozlowska, ...
Digestive and Liver Disease 41 (10), 762-764, 2009
522009
Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from …
W Park, MJ Lim, P Miranda, M Brzosko, P Wiland, S Gutierrez-Urena, ...
Arthritis and Rheumatism 65 (12), 2013
492013
Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries
M Péntek, G Poór, P Wiland, M Olejárová, M Brzosko, C Codreanu, ...
The European Journal of Health Economics 15, 35-43, 2014
482014
Stanowisko Zespołu Ekspertów Konsultanta Krajowego ds. Reumatologii w sprawie diagnostyki i terapii reumatoidalnego zapalenia stawów
W Tłustochowicz, M Brzosko, A Filipowicz-Sosnowska, P Głuszko, ...
Rheumatologia 46 (3), 2008
482008
Serum interleukin-18, fetuin-A, soluble intercellular adhesion molecule-1, and endothelin-1 in ankylosing spondylitis, psoriatic arthritis, and SAPHO syndrome
H Przepiera-Będzak, K Fischer, M Brzosko
International journal of molecular sciences 17 (8), 1255, 2016
462016
Factors associated with quality of life in systemic sclerosis: a cross-sectional study
M Sierakowska, H Doroszkiewicz, J Sierakowska, M Olesińska, ...
Quality of Life Research 28, 3347-3354, 2019
452019
Biosimilar switching–current state of knowledge
P Wiland, B Batko, M Brzosko, E Kucharz, W Samborski, J Świerkot, ...
Reumatologia/Rheumatology 56 (4), 234-242, 2018
422018
High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis
O Kowal-Bielecka, M Bielecki, S Guiducci, B Trzcinska-Butkiewicz, ...
Arthritis Research & Therapy 15, 1-11, 2013
412013
The distribution of human endogenous retrovirus K-113 in health and autoimmune diseases in Poland
M Krzysztalowska-Wawrzyniak, M Ostanek, J Clark, A Binczak-Kuleta, ...
Rheumatology 50 (7), 1310-1314, 2011
412011
Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial
JM Kremer, R Blanco, AM Halland, M Brzosko, R Burgos-Vargas, ...
Clin Exp Rheumatol 34 (4), 625-633, 2016
402016
系统目前无法执行此操作,请稍后再试。
文章 1–20